Skip to main content
S&P 5007,691.02+1.61%DOW53,363.17+3.04%NASDAQ25,748.76+1.48%BTC$80,053.00+2.92%ETH$2,414.72+5.49%GOLD$4,073.50+3.38%OIL$88.61-7.78%
Smart Investors Daily
SID Premium
HE

NASDAQ · HEPA

Hepion Pharmaceuticals, Inc.

Healthcare · Biotechnology

$0.14

Down-$0.01 (-6.25%)

Updated Nov 4, 2026, 8:19 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
777.4K
P/E ratio
-0.06
Dividend yield
0.00%
52-week range
$0.03 – $0.62
Volume
25.11K
Avg. volume
29.96K

Price performance · HEPA

HEPA price history

1M range · 0 trading sessions · Daily adjusted prices

HEPA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest HEPA news

The latest Smart Investors Daily articles mentioning HEPA.

Stock researchCompany · Overview

HEPA research

Overview

Company profile and research snapshot.

Company profile

HEPION PHARMS INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$70.00
Implied upside
—
Analysts
—
HEPA recent ratings
DateFirmRatingTarget
Dec 7, 2023Brookline CapitalHold—
Feb 28, 2022Cantor FitzgeraldOverweight—
Nov 22, 2019Brookline CapitalBuy—
Mar 20, 2019Maxim GroupHold—
Jul 10, 2018Maxim GroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest

\- In a simulation of 200 virtual subjects, a single dose of GV104 (16 mg nalmefene buccal film) taken at least 15 minutes before exposure prevented every potential fentanyl-induced cardiac arrest, at intravenous fentanyl doses known to be lethal in humans -\- FDA re-affirmed the overall approach and provided comments that will improve the Company's ability to "demonstrate long-term prophylactic protection" -\- The FDA comments are an important step in the path leading to an NDA. The Company int

Yahoo · Oct 19, 2026

Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication

(OTCQB:HEPA) ("Hepion" or the "Company"), a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases, today announced that its wholly-owned subsidiary Gravitas Life Sciences, LLC ("GLS"), a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation, has received written responses from the U. Food and Drug Administration ("FDA"or "Agency") to its Type B pre-Investigational

Yahoo · Oct 14, 2026

Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

(OTCQB:HEPA) ("Hepion" or the "Company"), a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases, today announced that it has completed the acquisition of Gravitas Life Sciences, LLC ("GLS"), a clinical-stage biotechnology company developing therapeutic candidates in immunology and inflammation. The transaction closed on October 6, 2026, and GLS is now a wholly-owned subsidiary of the Company.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By